| Titre : | ASSESSMENT OF MOLECULAR BIOMARKERS FOR BLADDER CANCER DIAGNOSIS, PROGNOSIS AND THERAPY | | Type de document : | thèse | | Auteurs : | Hajar EL AHANIDI, Auteur | | Année de publication : | 2022 | | Langues : | Anglais (eng) | | Mots-clés : | Bladder cancer Telomerase Immune Checkpoint Molecular Biomarkers Cancer de la Vessie Télomérase Checkpoint Immunitaire Biomarqueurs Moléculaires سرطان المثانة التيلوميراز نقط التفتيش المناعتي المؤشرات الحيوية الجزيئية | | Résumé : | Bladder cancer is one of the most common malignancies world-wide. Even though bladder cancer is the fourth
most commonly diagnosed cancer in men and accounted for 3.6% of total deaths in 2020, it has historically
been less studied compared to other common types of cancer.
During the last decade our knowledge of the disease has increased greatly through extensive molecular profiling.
Bladder cancer has now been studied on the transcriptomic, genomic, epigenomic, and proteomic level and the
results are on the verge of clinical translation. Detection, risk stratification, and treatment response prediction
are just a few of the key areas where the molecular research can help improve the management of bladder cancer.
In parallel, we have also witnessed a revolutionary advancement in cancer therapy thanks to the rise of
immunotherapies which holds great promise for cancer patients.
Currently, the major challenge in bladder cancer monitoring is the prevention of disease recurrence and
improvement of therapy, especially for patients with advanced tumoral stages that are eligible for immune
checkpoint inhibitors use. The low patient survival rates, as well as the failure of new immunotherapies in about
80% of bladder cancer patients, emphasize the need of therapy improvements and to highlight new therapeutic
strategies.
During my PhD, we focused on the molecular characterization of a broad collection of bladder cancer specimen
and conduct a study where we evaluated several genetic and epigenetic biomarkers that can be involved in
bladder carcinogenesis and in modulating immunosuppressive genes and induce immunotherapy failure in
eligible patients.
The overarching aim of the research papers included in this thesis has been to further improve our understanding
of the molecular biology of the disease and contribute to the improvement of bladder cancer patients’ lives.
| | Numéro (Thèse ou Mémoire) : | D0032022 | | Président : | Azeddine IBRAHIMI | | Directeur : | Ahmed AMEUR ; Mohammed ATTALEB | | Juge : | Mohammed EL MZIBRI | | Juge : | Camilla JANDUS ; ABABOU ; | | Juge : | MounaMouhcine BENNANI MECHITA ; Mouhcine BENNANI ;Abderrahm |
ASSESSMENT OF MOLECULAR BIOMARKERS FOR BLADDER CANCER DIAGNOSIS, PROGNOSIS AND THERAPY [thèse] / Hajar EL AHANIDI, Auteur . - 2022. Langues : Anglais ( eng) | Mots-clés : | Bladder cancer Telomerase Immune Checkpoint Molecular Biomarkers Cancer de la Vessie Télomérase Checkpoint Immunitaire Biomarqueurs Moléculaires سرطان المثانة التيلوميراز نقط التفتيش المناعتي المؤشرات الحيوية الجزيئية | | Résumé : | Bladder cancer is one of the most common malignancies world-wide. Even though bladder cancer is the fourth
most commonly diagnosed cancer in men and accounted for 3.6% of total deaths in 2020, it has historically
been less studied compared to other common types of cancer.
During the last decade our knowledge of the disease has increased greatly through extensive molecular profiling.
Bladder cancer has now been studied on the transcriptomic, genomic, epigenomic, and proteomic level and the
results are on the verge of clinical translation. Detection, risk stratification, and treatment response prediction
are just a few of the key areas where the molecular research can help improve the management of bladder cancer.
In parallel, we have also witnessed a revolutionary advancement in cancer therapy thanks to the rise of
immunotherapies which holds great promise for cancer patients.
Currently, the major challenge in bladder cancer monitoring is the prevention of disease recurrence and
improvement of therapy, especially for patients with advanced tumoral stages that are eligible for immune
checkpoint inhibitors use. The low patient survival rates, as well as the failure of new immunotherapies in about
80% of bladder cancer patients, emphasize the need of therapy improvements and to highlight new therapeutic
strategies.
During my PhD, we focused on the molecular characterization of a broad collection of bladder cancer specimen
and conduct a study where we evaluated several genetic and epigenetic biomarkers that can be involved in
bladder carcinogenesis and in modulating immunosuppressive genes and induce immunotherapy failure in
eligible patients.
The overarching aim of the research papers included in this thesis has been to further improve our understanding
of the molecular biology of the disease and contribute to the improvement of bladder cancer patients’ lives.
| | Numéro (Thèse ou Mémoire) : | D0032022 | | Président : | Azeddine IBRAHIMI | | Directeur : | Ahmed AMEUR ; Mohammed ATTALEB | | Juge : | Mohammed EL MZIBRI | | Juge : | Camilla JANDUS ; ABABOU ; | | Juge : | MounaMouhcine BENNANI MECHITA ; Mouhcine BENNANI ;Abderrahm |
|
Accueil
Faire une suggestion Affiner la rechercheASSESSMENT OF MOLECULAR BIOMARKERS FOR BLADDER CANCER DIAGNOSIS, PROGNOSIS AND THERAPY / Hajar EL AHANIDI
